PE20081167A1 - Sal de alisquireno - Google Patents

Sal de alisquireno

Info

Publication number
PE20081167A1
PE20081167A1 PE2007001529A PE2007001529A PE20081167A1 PE 20081167 A1 PE20081167 A1 PE 20081167A1 PE 2007001529 A PE2007001529 A PE 2007001529A PE 2007001529 A PE2007001529 A PE 2007001529A PE 20081167 A1 PE20081167 A1 PE 20081167A1
Authority
PE
Peru
Prior art keywords
salt
alisquirene
refers
orotic acid
aldosterone
Prior art date
Application number
PE2007001529A
Other languages
English (en)
Inventor
Jean-Louis Reber
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38002048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081167A1 publication Critical patent/PE20081167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA SAL DE ALISQUIRENO DE FORMULA (I) CON ACIDO OROTICO (VITAMINA B13) QUE PRESENTA UN PATRON DE DIFRACCION EN POLVO DE RAYOS X CON LOS SIGUIENTES PICOS EXPRESADOS EN GRADOS 2 TETA: 4.4(st), 8.7(m), 10.5(w), 14.4(m), 17.7(st), 19.3(m), 19.9(w), 20.8(w), 22.2(st), 23.0(m), 25.2(w), 26.8(m). DONDE LAS FORMAS DE DICHA SAL PUEDEN SER CRISTALINA, PARCIALMENTE CRISTALINA, AMORFA Y POLIMORFA. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE ADEMAS CONTIENEN UN ANTAGONISTA DE ALDOSTERONA, UN INHIBIDOR DE LA SINTASA DE ALDOSTERONA, UN DIURETICO, ENTRE OTROS; Y A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE A) DISOLVER LA BASE LIBRE DE ALISQUIRENO Y EL ACIDO OROTICO EN UN SOLVENTE ORGANICO; B) CONCENTRAR EL SOLVENTE DE LA SOLUCION MIXTA MEDIANTE CALENTAMIENTO HASTA LA PRECIPITACION; Y C) FILTRAR Y SECAR LA PASTA PARA OBTENER LA SAL. DICHA SAL ES UN INHIBIDOR DE RENINA
PE2007001529A 2006-11-09 2007-11-07 Sal de alisquireno PE20081167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06123758 2006-11-09

Publications (1)

Publication Number Publication Date
PE20081167A1 true PE20081167A1 (es) 2008-10-03

Family

ID=38002048

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001529A PE20081167A1 (es) 2006-11-09 2007-11-07 Sal de alisquireno

Country Status (16)

Country Link
US (1) US20100130616A1 (es)
EP (1) EP2089356B1 (es)
JP (1) JP2010509254A (es)
KR (1) KR20090081010A (es)
CN (1) CN101528672A (es)
AR (1) AR063597A1 (es)
AT (1) ATE555082T1 (es)
AU (1) AU2007316878B2 (es)
BR (1) BRPI0718701A2 (es)
CA (1) CA2665073A1 (es)
CL (1) CL2007003216A1 (es)
MX (1) MX2009004628A (es)
PE (1) PE20081167A1 (es)
RU (1) RU2456267C2 (es)
TW (1) TW200838836A (es)
WO (1) WO2008055669A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205232A2 (en) * 2007-09-28 2010-07-14 Novartis Ag Galenical formulations of aliskiren
CA2724746A1 (en) * 2008-05-23 2009-11-26 Teva Pharmaceuticals Industries Ltd. Aliskiren monofumarate and processes for preparation thereof
WO2010091277A2 (en) 2009-02-05 2010-08-12 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
WO2010089105A2 (en) 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
JP4900755B2 (ja) * 2000-07-05 2012-03-21 ノバルティス ファーマ アーゲー 置換オクタノイルアミドの調製方法
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
CA2534664C (en) * 2003-09-04 2012-10-30 Cephalon, Inc. Modafinil compositions
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos

Also Published As

Publication number Publication date
AU2007316878B2 (en) 2011-07-14
TW200838836A (en) 2008-10-01
US20100130616A1 (en) 2010-05-27
RU2456267C2 (ru) 2012-07-20
AU2007316878A1 (en) 2008-05-15
ATE555082T1 (de) 2012-05-15
WO2008055669A1 (en) 2008-05-15
AR063597A1 (es) 2009-02-04
CL2007003216A1 (es) 2008-06-13
JP2010509254A (ja) 2010-03-25
RU2009121646A (ru) 2010-12-20
MX2009004628A (es) 2009-05-15
EP2089356B1 (en) 2012-04-25
CA2665073A1 (en) 2008-05-15
KR20090081010A (ko) 2009-07-27
EP2089356A1 (en) 2009-08-19
CN101528672A (zh) 2009-09-09
BRPI0718701A2 (pt) 2013-12-31

Similar Documents

Publication Publication Date Title
AR077242A1 (es) Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades.
CO6410293A2 (es) Nueva formula cristalina vi de la agomelatina preparación y uso de la misma
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
RU2013109393A (ru) Безилатная соль ингибитора втк
DOP2010000387A (es) Compuestos pirazolicos 436
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
UY30472A1 (es) Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones.
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
PE20081167A1 (es) Sal de alisquireno
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
MX2009000281A (es) Derivados tetrahidroisoquinolina, metodos de preparacion y usos medicinales de los mismos.
BRPI0606923A2 (pt) substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica
BR112017007953A2 (pt) forma cristalina de um bissulfato inibidor de jak quinase e método de preparação desse
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
UY28911A1 (es) Profármacos de esteroides con acción androgénica

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed